Needham Maintains Buy on Selecta Biosciences, Lowers Price Target to $6

Needham analyst Gil Blum maintains Selecta Biosciences (NASDAQ:SELB) with a Buy and lowers the price target from $7 to $6.

Needham analyst Gil Blum maintains Selecta Biosciences (NASDAQ:SELB) with a Buy and lowers the price target from $7 to $6.

Total
0
Shares
Related Posts